The global anti-fungal therapy market valuation was USD 13.8 billion in 2022 and is expected to expand at a CAGR of 4.7% from 2023 to 2033. The market is projected to reach USD 22.8 billion by 2033. The azoles segment is leading the market by drug class with a share of about 29.1% in 2022.
| Data Points | Market Insights |
|---|---|
| Anti-fungal Therapy Market Size, 2022 | USD 13.8 Billion |
| Anti-fungal Therapy Market Value, 2023 | USD 14.4 Billion |
| Anticipated Market Value, 2033 | USD 22.8 Billion |
| Value-based CAGR (2023 to 2033) | 4.7% |
| Market Share of Top 5 Countries | 52.3% |
| Key Market Players | Eli Lilly and Company, Sanofi S.A, Abbott Laboratories, Arcadia Consumer Healthcare Inc., Astellas Pharma Inc, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis A.G, Gilead Sciences Inc., Johnson & Johnson’s, MerzPharma, Enzon Pharmaceuticals Inc., Glenmark, Dr. Reddy's Laboratories, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Apotex Inc., Zydus Cadila, Aurobindo Pharma, Cipla Inc., Dr. Reddy's Laboratories Ltd., Pfizer Inc., Torrent Pharmaceuticals Ltd., Bayer AG. |
Rapid initiation of antifungal therapy is essential in the management of fungal diseases that target either the plasma membrane or the cell wall. Increasing perception rates of primary classes of antifungal agents act as a driver for the growth of the antifungal drugs and therapies market.
The efforts of government and private organizations to raise awareness about various fungal illnesses are projected to boost the anti-fungal drugs market. Furthermore, an increase in fungal infection cases such as aspergillosis and candidiasis is one of the major reasons driving the growth of the anti-microbial/anti-fungal test market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market share for anti-fungal therapies was around 30.8% of the overall global antibiotics market, which was worth USD 42.5 billion in 2022. The market grew at a CAGR of 3.0% during the historical period.
| Historical CAGR (2017 to 2022) | 3.0% |
|---|
The demand for anti-fungal therapies expanded at a CAGR of 4.7% from 2023 to 2033, owing to the rising cases of fungal diseases like candidiasis, aspergillosis and onychomycosis.Anti-fungal therapies are widely employed in the mycosis control and treatment/mycosis management market.
People are looking for products that would promote faster recovery and prevention of fungal diseases. Over the forecast period, the market is projected to be driven by the pharmaceutical industries’ formulations and the ongoing developments in the discovery of novel treatments for fungal diseases.
For instance, on 7 June 2022, the USA Food and Drug Administration (FDA) approved the use of Sanofi Dupixent (dupilumab) for children who are six months to 5 years old with moderate-to-severe atopic dermatitis.
Furthermore, the market for anti-fungal therapies is growing due to rising new drug development and clinical trials activities. For instance, three novel antifungals are undergoing phase II and phase III clinical studies, namely rezafungin, olorofim, and fosmanogepix by Amplyx Pharmaceuticals, which were acquired by Pfizer in April 2022.
The market is anticipated to grow as a result of an increase in initiatives by private and public organizations to spread awareness about a variety of fungal illnesses. For instance, CDC (Centres For Disease Control And Prevention) and its partners organized Fungal Disease Awareness Week, September 20-24, 2022. The purpose of this program is to highlight the importance of detecting and diagnosing serious fungal diseases early in patients to provide life-saving treatment.
Fungal infections of the eyes, mouth, and skin, including superficial and systematic infections, are projected to fuel market expansion. The availability and effective adoption of generic antifungal drugs like miconazole, clotrimazole, and econazole for the treatment of fungal infections create significant opportunities in the market. Anti-fungal therapies that doctors strongly prescribe for patients to treat fungal infections are also considered one of the key factors in boosting the market.
Principal Consultant
Sometimes, antifungal therapy is harmful to the patient and causes side effects such as heart arrhythmia, oliguria, promethazine and muscle spasms or pain. For instance, according to the National Library of Medicine, amphotericin B deoxycholate therapy is known to cause side effects like chills, the risk of hypotension, migraines, hypomagnesemia, renal insufficiency, emesis, rigors, and pyrexia.
The market is expected to be hampered by strict government regulations, patent expirations, an increase in fungal resistance to drugs, etc., during the projected period. Furthermore, it is anticipated that rising drug recall rates may hamper the market's expansion. These factors cumulatively propose a negative effect on the growth of the anti-fungal therapy market.
| Country | CAGR (2023 to 2033) |
|---|---|
| United States | 4.8% |
| India | 4.2% |
| China | 4.4% |
| Germany | 3.8% |
| United Kingdom | 3.9% |
The United States anti-fungal therapy market is expected to grow at a CAGR of 4.8% over the forecast period.
A major driver of the market expansion for anti-fungal therapies in the United States is the rising prevalence of fungal infections among people. For instance, according to Oxford University Press, 666,235 cases of fungal infections were identified in the United States. Infections with pneumocystis, candida, and aspergillus accounted for 76.3% of reported fungal infections and 81.1% of related treatment costs.
Key players in the United States engage in non-organic actions, such as mergers and acquisitions, to expand their antifungal therapy drug portfolio. This is a key element driving the demand for antifungal medications in the USA
Germany held around 32.9% share of the European market in 2022, due to the prevalence of allergic fungal diseases like aspergillosis and dermatophytosis. The market in Germany is expected to grow at a CAGR of 3.8% through 2033.
Fungal infections are considered a significant public health issue in Germany. Germany will see profitable growth as more and more pharmaceutical drugs are manufactured for various fungal diseases. For instance, in 2018, Pfizer started new manufacturing units for anti-fungal medicines in Germany.
In addition, the provision of public health advocacy for people with fungal diseases is another area where the government and other private groups are investing heavily, and it is anticipated to drive the market for anti-fungal therapies in Germany.
The market in India is set to exhibit a CAGR of 4.2% over the forecast period.
In India, strong financing and the launch of several healthcare programs like Pradhan Mantri Jan Arogya Yojana and Ayushman Bharat offer free healthcare facilities and reimbursement options to patients receiving healthcare treatment. This is boosting the demand for anti-fungal therapy market.
Increasing disposable incomes of middle-class families enable them to spend more money on their healthcare expenditure to get high-quality treatment facilities. The market is expected to grow more quickly throughout the forecast period due to increased expenditure on continued research and development for anti-fungal drug innovations. Increasing awareness of fungal infection and the adoption of antifungal drugs are driving the anti-fungal therapy market.
The market in the United Kingdom is expected to rise at a CAGR of 3.9% through 2033.
In the United Kingdom, accessibility of antifungal drugs and rising awareness among healthcare professionals are expected to drive the market in the United Kingdom. The United Kingdom has a well-established healthcare system, and antifungal therapies are prescribed to patients only by healthcare professionals.
The market in China is expected to rise at a CAGR of 4.4% through 2033. Rapid urbanization, evolving lifestyle, and increasing healthcare awareness boost sales of antifungal drugs in China. Also, the healthcare system in China has been evolving, and access to healthcare services has improved in recent years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Top Drug Class | Azoles |
|---|---|
| Market Share | 29.1% |
Azoles constitute a share of 29.1% of the anti-fungal therapy industry share by drug class. The increasing cases of fungal diseases like blastomycosis, histoplasmosis, and ringworm are contributing to market expansion. Azoles prevent the formation of fungus sterols. Azole antifungal agents help in the treatment of systemic fungal infections, contributing to market expansion.
| Top Indication | Candidiasis |
|---|---|
| Market Share | 35.0% |
The candidiasis segment holds a share of 35.0% of the market by indication. The most common fungal infection is candidiasis, which is caused by yeast. The rising cases of candidiasis are driving the anti-fungal therapy market.
| Top Route of Administration | Topical |
|---|---|
| Market Share | 53.7% |
The topical route of administration of drugs is more preferred by patients compared to oral and parenteral. The topical segment holds a prominent market share of 53.7%, rising at a CAGR of 4.7% over the forecast period. Topical formulation is less expensive than oral formulation and has fewer adverse side effects. Also, the topical route of administration has a higher retention rate and direct access, further propelling the demand for anti-fungal therapies.
| Top Distribution Channel | Retail Pharmacies |
|---|---|
| Market Share | 44.0% |
Retail pharmacies hold a prominent share of 44.0% of the market by distribution channels. The growing prevalence of antifungal infections like dermatophytosis, aspergillus, and superficial mycoses and the developments in drug discovery have driven this segment’s growth, propelling the anti-fungal therapy market.
The market for the production of anti-fungal therapies/drugs is fragmented due to the presence of several key players. These businesses are employing strategies including collaborations, partnerships, mergers and acquisitions, and new product launches to satisfy consumer demand and increase their client base. Also, governments are focusing on taking initiatives to invest in mobility equipment and enhance the anti-fungal drug and therapy market dynamics.
Recent Developments in the Anti-fungal Therapy Market
Similarly, more recent developments related to anti-fungal therapies/drugs have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD Billion for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Nordic countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, Israel, South Africa and North Africa |
| Key Market Segments Covered | Drug Class, Indication, Route of Administration, Distribution Channel and Region |
| Key Companies Profiled | Eli Lilly and Company, Sanofi S.A, Abbott Laboratories, Arcadia Consumer Healthcare Inc., Astellas Pharma Inc, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis A.G, Gilead Sciences Inc., Johnson & Johnson’s, MerzPharma, Enzon Pharmaceuticals Inc., Glenmark, Dr. Reddy's Laboratories, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Apotex Inc., Zydus Cadila, Aurobindo Pharma, Cipla Inc., Dr. Reddy's Laboratories Ltd., Pfizer Inc., Torrent Pharmaceuticals Ltd., Bayer AG |
| Pricing | Available upon Request |
The global anti-fungal therapy market was worth USD 13.8 billion in 2022 and is set to grow at a CAGR of 4.7% over the next ten years.
Rising prevalence of fungal infections such as candidiasis and adoption of anti-fungal therapies.
The United States, India, China, Germany, and the United Kingdom are expected to drive demand for anti-fungal therapies.
The market is expected to reach USD 22.8 billion by 2033, with sales revenue expected to register a 4.7% CAGR over the forecast period.
Demand for anti-fungal therapies in Europe is expected to register a growth rate of 4.2% through 2033.
The market in India is projected to grow at a CAGR of 4.2% over the forecast period.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Key Success Factors 5. Market Background 6. Global Market Demand Value or Size in (USD Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class 7.1. Azoles 7.2. Polyene Macrolides 7.3. Echinocandins 7.4. Allylamines 7.5. Others 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication 8.1. Dermatophytosis 8.2. Aspergillosis 8.3. Candidiasis 8.4. Others 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route of Administration 9.1. Oral 9.2. Topical 9.3. Parenteral 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel 10.1. Retail Pharmacies 10.2. Hospital Pharmacies 10.3. Online Pharmacies 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 11.1. North America 11.2. Latin America 11.3. Europe 11.4. East Asia 11.5. South Asia 11.6. Oceania 11.7. Middle East and Africa (MEA) 12. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 13. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033 19. Market Structure Analysis 20. Competition Analysis 20.1. Eli Lilly and Company 20.2. Sanofi S.A 20.3. Abbott Laboratories 20.4. Arcadia Consumer Healthcare Inc. 20.5. Astellas Pharma Inc. 20.6. GlaxoSmithKline Plc 20.7. Merck & Co. Inc. 20.8. Novartis AG 20.9. Gilead Sciences Inc. 20.10. Johnson & Johnson 20.11. MerzPharma 20.12. Enzon Pharmaceuticals Inc. 20.13. Glenmark 20.14. Dr. Reddy's Laboratories 20.15. F. Hoffmann-La Roche Ltd. 20.16. Teva Pharmaceutical Industries Ltd. 20.17. Hikma Pharmaceuticals PLC 20.18. Sun Pharmaceutical Industries Ltd. 20.19. Apotex Inc. 20.20. Zydus Cadila 20.21. Aurobindo Pharma 20.22. Cipla Inc. 20.23. Pfizer Inc. 20.24. Torrent Pharmaceuticals Ltd. 20.25. Bayer AG 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Anti-fungal Therapy Market
